

Published in final edited form as:

Nat Rev Cancer. 2010 March ; 10(3): 181–193. doi:10.1038/nrc2809.

Eicosanoids and cancer

Dingzhi Wang* and Raymond N. DuBois*[†]

*Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030–4009, USA

[†]Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030–4009, USA

Abstract

Eicosanoids, including prostaglandins and leukotrienes, are biologically active lipids that have been implicated in various pathological processes, such as inflammation and cancer. This Review highlights our understanding of the intricate roles of eicosanoids in epithelial-derived tumours and their microenvironment. The knowledge of how these lipids orchestrate the complex interactions between transformed epithelial cells and the surrounding stromal cells is crucial for understanding tumour evolution, progression and metastasis. Understanding the molecular mechanisms underlying the role of prostaglandins and other eicosanoids in cancer progression will help to develop more effective cancer chemopreventive and/or therapeutic agents.

A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are risk factors for cancer^{1–3}. Epidemiological and animal studies provide evidence that a high-fat diet can be associated with an increased risk for cancer, in particular colorectal, breast, pancreatic and prostate cancer³. Arachidonic acid is one major ingredient of animal fats and the biologically active lipids derived from this substrate have crucial roles in chronic inflammation and cancer. The metabolism of arachidonic acid by cyclooxygenase (COX), lipoxygenase (LOX) and P450 epoxygenase pathways generates eicosanoids, including prostanoids, leukotrienes, hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and hydroperoxyeicosatetraenoic acids (HPETEs) (FIG. 1). Epidemiological, clinical and animal studies provide evidence that activation of COX and LOX pathways during chronic inflammation and carcinogenesis results in aberrant metabolism of arachidonic acid, which may be one mechanism for the contribution of dietary fats to carcinogenesis.

Non-steroidal anti-inflammatory drugs (NSAIDs) have been reported to have beneficial effects on reducing the risk of developing some solid tumours, including the four most prevalent

© 2010 Macmillan Publishers Limited. All rights reserved

Correspondence to R.N.D., rdubois@mdanderson.org.

Competing interests statement

The authors declare no competing financial interests.

DATABASES

Entrez Gene: <http://www.ncbi.nlm.nih.gov/genePtges>

National Cancer Institute Drug Dictionary: <http://www.cancer.gov/drugdictionary/celecoxib>

UniProtKB: <http://www.uniprot.org>

[5-LOX](#) | [12-LOX](#) | [15-LOX-1](#) | [15-LOX-2](#) | [BLT1](#) | [BLT2](#) | [CCR7](#) | [COX1](#) | [COX2](#) | [CysLT1](#) | [CysLT2](#) | [DP](#) | [EGFR](#) | [EP1](#) | [EP2](#) | [EP3](#) | [EP4](#) | [FLAP](#) | [FP](#) | [GPR44](#) | [IP](#) | [PPARδ](#) | [PPARγ](#) | [PTGDS](#) | [TP](#)

FURTHER INFORMATION

Raymond N. DuBois' homepage: http://faculty.mdanderson.org/Raymond_DuBois/Default.asp?SNID=310943223

cancers worldwide: breast, colon, lung and prostate cancer⁴. NSAIDs exert some of their anti-inflammatory and anti-tumour effects by reducing prostanoid production through the inhibition of COX enzyme activity. In addition, emerging evidence suggests that LOX pathways are also involved in carcinogenesis. In general, 5-LOX (also known as ALOX5) and 12-LOX (also known as ALOX12) have potential procarcinogenic roles, whereas 15-LOX-2 (also known as ALOX15B) is thought to have an anti-carcinogenic effect, and the role of 15-LOX-1 (also known as ALOX15) remains controversial⁵. As 5-LOX has been shown to have a major role in carcinogenesis, understanding the contribution of each COX-derived prostanoid and 5-LOX-derived leukotriene in the pathogenesis of cancer could enable identification of new and safer therapeutic and chemopreventive agents with reasonable benefit and fewer side effects.

In this Review, we focus on recent insights into the roles of prostanoids and leukotrienes in several epithelial-derived malignancies, from their involvement in governing tumour epithelial cell proliferation, survival, and migration and invasion to their involvement in adapting the tumour microenvironment by influencing angiogenesis, inflammation and immunosuppression.

Prostanoid and leukotriene biosynthesis

The importance of the prostanoid and leukotriene biosynthetic pathway in carcinogenesis and chronic inflammation is supported by population studies, clinical trials and animal experiments. COX enzymes (correctly referred to as prostaglandin G/H synthases) exist in two isoforms: COX1 (also known as PTGS1) and COX2 (also known as PTGS2). *COX2* is an immediate-early response gene that is normally absent from most cells but is highly induced at sites of inflammation and during tumour progression⁶. Our laboratory was the first to report that *COX2* expression is upregulated in colorectal cancer⁷. Multiple follow-up studies have revealed that *COX2* levels are increased in other premalignant and malignant solid tumours, including those of the stomach, oesophagus, liver, pancreas, head and neck, lung, breast, prostate and bladder, and increased *COX2* expression is associated with decreased survival among these cancer patients⁸. By contrast, *COX1* was thought to be a housekeeping enzyme responsible for maintaining basal prostanoid levels that are important for tissue homeostasis. However, upregulation of *COX1* expression has been observed in ovarian cancer⁹. Although most attention has been focused on the cyclooxygenase pathway, a few reports have indicated that 5-LOX is generally absent in normal epithelia but is induced by pro-inflammatory stimuli and is often constitutively expressed in various epithelial cancers including those of the colon, oesophagus, lung, prostate and breast⁵. As other LOX isoforms are not involved in leukotriene synthesis, the relevance of their expression and function is not included in this Review.

At a glance

- The altered metabolism of arachidonic acid by cyclooxygenase (COX) and lipoxygenase (LOX) is a common feature of several epithelial-derived malignancies and has been shown to have crucial roles in cancer progression.
- The production of arachidonic acid-derived prostanoids and leukotrienes occurs in single cells or takes place in a complex manner in which these biologically active lipids, specifically leukotrienes, are generated by transcellular biosynthesis through the cooperation of multiple different types of cells in the tumour and inflamed tissues.
- Pro-inflammatory prostaglandins and leukotrienes promote tumour growth by regulating tumour epithelial cells themselves and orchestrating the complex interactions between transformed epithelial cells and surrounding stromal cells to

establish the tumour microenvironment that facilitates tumour-associated angiogenesis and evades attack by the immune system.

- Prostaglandins and leukotrienes can modulate tumour epithelial cell proliferation, apoptosis, and migration and invasion through multiple signalling pathways in both an autocrine and paracrine fashion.
- Prostaglandins and leukotrienes are central molecules in the regulation of stem cell homeostasis.
- Pro-inflammatory prostaglandins and leukotrienes are key mediators in the crosstalk between tumour epithelial cells and their surrounding stromal cells in establishing a tumour microenvironment with chronic inflammation and immunosuppression.
- Although non-steroidal anti-inflammatory drugs (NSAIDs), which target COX enzymes, are still among the most promising chemopreventive agents for cancer, cardiovascular and gastrointestinal side effects have dampened enthusiasm for their use as chemopreventive agents. Understanding the roles of prostaglandins and leukotrienes in epithelial-derived tumours and their microenvironment may help to develop cancer biomarkers and chemopreventive and/or therapeutic agents with a greater benefit and fewer side effects than NSAIDs.

Prostanoid biosynthesis

Cyclooxygenase enzymes catalyse the conversion of arachidonic acid to prostanoids, including prostaglandins and thromboxane A₂ (TXA₂) (FIG. 1). The prostaglandins exert their biological effects in an autocrine or paracrine manner by binding to their cognate cell surface receptors, which belong to the G protein-coupled receptor (GPCR) family. These receptors are designated DP (also known as PTGDR) and GPR44 for prostaglandin D₂ (PGD₂); EP1, EP2, EP3 and EP4 (also known as PTGER1, PTGER2, PTGER2 and PTGER4, respectively) for PGE₂; FP (also known as PTGFR) for PGF_{2 α} ; IP (also known as PTGIR) for PGI₂; and TP (also known as TBXA2R) for TXA₂. In some cases, however, certain prostaglandins and their metabolites bind nuclear receptors such as peroxisome proliferator-activated receptors (PPARs). For example, PGI₂ can transactivate PPAR δ , and a PGD₂ dehydration product, 15-deoxy- Δ 12,14-PGJ₂ (15dPGJ₂), is a natural ligand for PPAR γ . PGE₂ can also indirectly activate PPAR δ in certain contexts¹⁰. The specific action of the different prostaglandins in a particular type of tissue predominantly depends on the cell type-specific expression of their cognate receptors as well as prostaglandin production. In addition to their synthesis, the steady-state extracellular levels of prostaglandins also depend on a carrier-mediated transport process, as well as inactivation in the cytoplasm. These processes are regulated by prostaglandin transporter (PGT; an influx transporter), multidrug resistance-associated protein 4 (MRP4; an efflux transporter) and hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD; also known 15-PGDH). For example, PGE₂ and PGF_{2 α} are rapidly metabolized *in vivo* by 15-PGDH to a stable 13,14-dihydro-15-keto-PGE₂ (PGEM) and 13,14-dihydro-15-keto-PGF_{2 α} , respectively. Other prostaglandins are mainly metabolized in a non-enzymatic manner¹¹.

Leukotriene biosynthesis

The 5-LOX enzyme interacts with a 5-LOX-activating protein (FLAP) and converts arachidonic acid to the unstable leukotriene A₄ (LTA₄) through an HPETE. FLAP enhances the activity of 5-LOX by binding to arachidonic acid and presenting it to 5-LOX. LTA₄ is subsequently converted to 5-HETE, or hydrolysed into biologically active LTB₄ by LTA₄ hydrolase, or to the cysteinyl leukotriene (CysLT), LTC₄, by LTC₄ synthase. LTC₄ is then

converted to another CysLT, LTD₄, which is sequentially metabolized to LTE₄ (FIG. 1). LTB₄ and LTD₄ are the most potent leukotrienes. They exert their biological effects through the activation of GPCRs. LTB₄ can bind to two receptors, BLT1 (also known as LTB4R) with high affinity and BLT2 (also known as LTB4R2) with low affinity; CysLTs bind to at least two distinct receptors, CysLT1 (also known as CYSLTR1) and CysLT2 (also known as CYSLTR2). Like LTB₄ receptors, CysLT1 has a high affinity for CysLTs — which is higher for LTD₄ than LTC₄ — whereas CysLT2 has a lower overall affinity for CysLTs that is equal for LTD₄ and LTC₄. BLT1 and CysLT1 are exclusively expressed in leukocytes, whereas BLT2 and CysLT2 are expressed in a wide variety of cells.

Transcellular biosynthesis

Eicosanoid biosynthesis can occur in a single cell that contains the complete complement of enzymes, but the production of eicosanoids in a tissue, in particular in tumour tissues and sites of inflammation, takes place in a more complex manner in which some of these biologically active lipids, specifically leukotrienes, are generated by transcellular biosynthesis through the cooperation of multiple different cell types.

The leukotrienes are primarily produced by stimulated leukocytes that express the enzymes required for their synthesis. Epithelial and endothelial cells can also generate LTB₄, LTC₄ and LTD₄ at inflammatory sites through transcellular metabolism by which epithelial or endothelial cells use LTA₄ that is released from immune cells, in particular neutrophils, as epithelial and endothelial cells express LTA₄ hydrolase¹². However, leukocytes can also use arachidonic acid that is secreted from epithelial cells as a substrate to generate leukotrienes. Transcellular leukotriene biosynthesis has been observed during inflammation *in vivo*¹³. Therefore, the transcellular biosynthesis between epithelial or endothelial and immune cells can generate the overproduction of leukotrienes, which in turn further amplifies the inflammatory response. Additional research is needed to determine the extent of transcellular biosynthesis in the tumour microenvironment. To date, there is no published evidence demonstrating transcellular biosynthesis of prostaglandins between immune and epithelial cells, although this is reported to occur between platelets and endothelial cells¹².

Eicosanoids in cancer

Prostanoids and cancer

Among prostanoids, proinflammatory PGE₂ has a predominant role in promoting tumour growth. PGE₂ is the most abundant prostaglandin that is found in various human malignancies, including colon, lung, breast, and head and neck cancer, and is often associated with a poor prognosis¹⁴⁻¹⁷. By contrast, 15-PGDH is highly expressed in normal tissues but is ubiquitously lacking in human colon, gastric, lung and breast cancer¹⁸⁻²¹. Lack of 15-PGDH expression in these tumours results in increased endogenous PGE₂ levels. Multiple lines of evidence from mouse models of colorectal cancer (CRC) demonstrate that COX2-derived PGE₂ promotes tumour growth. PGE₂ treatment blocks NSAID-induced regression of small intestinal adenomas in *Apc^{Min/+}* mice²² and increased endogenous PGE₂ levels through the loss of 15-PGDH inhibit the anti-tumour effects of celecoxib in the azoxymethane (AOM) mouse model²³. Direct evidence that PGE₂ promotes tumour growth comes from recent studies showing that PGE₂ treatment dramatically increased both small and large intestinal adenoma burden in *Apc^{Min/+}* mice and significantly enhanced AOM-induced colon tumour incidence and multiplicity^{10,24}. Furthermore, increased endogenous PGE₂ through the genetic deletion of *15-Pgdh* promotes colon tumour growth in *Apc^{Min/+}* and AOM mouse models²⁵. By contrast, inhibition of endogenous PGE₂ through the genetic deletion of prostaglandin E synthase (*Ptges*) suppresses intestinal tumorigenesis in *Apc^{Min/+}* and AOM models²⁶. The central role of PGE₂ in colorectal tumorigenesis has been further confirmed by evaluating mice with a

homozygous deletion of individual PGE₂ receptors²⁷⁻²⁹. Limited information is available regarding the role of PGE₂ signalling in animal models of other cancers. Increased PGE₂ levels through the overexpression of COX2 and PTGES cause gastric tumorigenesis in *Wnt1*-transgenic mice driven by the keratin 19 (*Krt19*) promoter³⁰. Deletion of the EP2 receptor inhibits murine lung tumorigenesis that is induced by a chemical carcinogen³¹ and significantly suppresses COX2-induced mammary hyperplasia in mice³². Similarly, an EP1 antagonist inhibits chemically induced breast cancer development in rats³³. Collectively, these studies demonstrate that PGE₂ plays an important part in cancer progression.

The role of PGD₂ in carcinogenesis remains ambiguous. Disruption or overexpression of PGD₂ synthase (*PTGDS*) in *Apc*^{Min/+} mice accelerates or reduces intestinal tumour growth³⁴, suggesting that PGD₂ has anti-tumour effects. However, the evidence that genetic disruption of its receptor (*DP*) has no effect on colon tumour formation in the AOM mouse model does not support the hypothesis that PGD₂ has anti-tumour effects²⁸. One possible explanation for the differences in phenotype caused by *PTGDS* compared with *DP* in mouse models is that the PGD₂-derived product 15dPGJ₂ inhibits tumour growth by binding to PPAR γ . It is well established that the activation of PPAR γ inhibits tumour growth through anti-proliferative, pro-apoptotic, pro-differentiation and anti-angiogenic effects in cell lines and animal models³⁵. Alternatively, overexpression of *PTGDS* might shift the conversion of PGH₂ away from PGE₂, which in turn would suppress tumour growth. Further investigation is required to assess the role of PGD₂ and its receptors in cancer progression.

Little information regarding the role of other prostaglandins in animal models of cancer is available; however, disruption of FP, IP or TBXA₂R receptors does not affect colon tumour formation in the AOM mouse model²⁸, suggesting that these receptors are not involved in CRC progression. The question is now whether these receptors modulate tumour growth in other models of CRC or in other types of cancer. A role for PGF_{2 α} in tumorigenesis has been suggested as it can enhance carcinogen-induced transformation of fibroblasts *in vitro* through the induction of COX2 (REF. ³⁶). Activation of PPAR δ accelerates intestinal tumour growth in *Apc*^{Min/+} mice³⁷, supporting the idea that PGI₂ might promote colon tumour progression through this receptor. Further work is required to explore the role of PGI₂ in colon carcinogenesis and other cancers.

Leukotrienes and cancer

Compared with prostaglandins, much less is known about the pro-inflammatory leukotrienes in cancer. However, emerging data suggest that leukotrienes can have an important role in carcinogenesis.

LTB₄ levels are increased in human colon and prostate cancer^{38,39}, and the expression of LTB₄ receptors is increased in human pancreatic cancer⁴⁰. LTB₄ expression is also increased in HRAS-v12-transformed cells and the receptor BLT2 is required for Ras-induced transformation *in vivo*⁴¹. Furthermore, inhibition of LTB₄ synthesis by treatment with an LTA₄ hydrolase inhibitor, bestatin, reduced the burden of oesophageal adenocarcinoma in a rat model⁴².

The CysLT1 receptor is highly expressed in human colon and prostate cancers and negatively correlates with patient survival^{43,44}. Increased CysLT1 expression in CRC correlates with the ability of LTD₄ to induce proliferation and inhibit apoptosis. By contrast, reduced expression of the CysLT2 receptor is associated with a poor prognosis in patients with CRC, and CysLT2 signalling is involved in inducing apoptosis and terminal differentiation⁴⁵. However, comparatively little is known about the effects of CysLT2 on signalling and biological function.

Mechanisms of eicosanoids in carcinogenesis

To understand the mechanism(s) underlying the effects of prostaglandins and leukotrienes on cancer progression, researchers have been investigating precisely how these lipids affect cancer biology. As mentioned earlier, pro-inflammatory eicosanoids are abundantly produced by various types of cancer cells and their surrounding cells. These biologically active lipids can modulate tumour progression through several mechanisms, such as by directly activating their receptors on tumour epithelial cells to regulate cell proliferation, apoptosis, migration and invasion; directly inducing epithelial cells to secrete growth factors, pro-inflammatory mediators and angiogenic factors that switch a normal microenvironment to one that supports tumour growth and spread; and directly binding receptors on stromal cells to promote a tumour-supportive microenvironment by inducing angiogenesis and evading attack by the immune system (FIG. 2).

The role of prostaglandins and leukotrienes in tumour epithelial cells

Prostaglandins and leukotrienes can modulate tumour cell proliferation, differentiation and apoptosis through multiple signalling pathways in both an autocrine and paracrine fashion (FIG. 3; TABLE 1). PGE₂ induces proliferation by activating at least two signalling pathways: Ras–Erk and glycogen synthase kinase-3β (GSK3β)–β-catenin in colon and lung cancer cells^{46–48}. In breast cancer, PGE₂ can upregulate aromatase production in stromal fat cells and concomitantly oestrogen production, which stimulates tumour cell proliferation⁴⁹. In addition, PGE₂ promotes colon tumour cell survival by activating a PI3K–Akt–PPARδ cascade in *Apc^{Min/+}* mice¹⁰. PGE₂ upregulation of BCL-2, an anti-apoptotic protein, and induction of nuclear factor-κB (NF-κB) transcriptional activity might also be involved in PGE₂-induced inhibition of apoptosis^{50,51}. Similarly, PGF_{2α} induces cell proliferation through an FP–Erk–fibroblast growth factor 2 (FGF2)–FGF receptor 1 (FGFR1)–Erk cascade in endometrial tumour cell lines⁵². By contrast, PGD₂ secreted by stromal cells inhibits prostate tumour cell growth *in vitro* through a PPARγ-dependent mechanism⁵³.

Knock down of LTA₄ hydrolase inhibits anchorage-independent growth of HCT-116 colon cancer cells, suggesting that leukotrienes are involved in cell growth regulation⁵⁴. Indeed, LTA₄ hydrolase-derived LTB₄ stimulates cell proliferation and promotes cell survival through a BLT1–Erk pathway in colon tumour cell lines⁵⁵, and induces cell proliferation through both Mek–Erk and PI3K–Akt pathways in human pancreatic cancer cell lines⁵⁶. Activation of the LTD₄–CysLT1 axis promotes cell proliferation and survival through multiple parallel pathways such as GSK3β–β-catenin, protein kinase C (PKC)–Raf–ERK1 and ERK2, BCL-2 and COX2 in non-transformed human intestinal epithelial cell lines^{57–59} and induces cell proliferation but not survival in CRC cell lines⁶⁰. By contrast, inhibition of LTD₄ signalling by a CysLT1 antagonist can induce apoptosis in prostate cancer cell lines⁴⁴. The LTD₄ induction of COX2, as well as PGE₂ production, implies that crosstalk exists between the 5-LOX and COX2 pathways. Consistent with the negative correlation of CysLT₂ expression with a poor prognosis in patients with CRC, CysLT₂ signalling leads to terminal differentiation and growth inhibition in colon carcinoma cell lines⁴⁵.

In addition, prostaglandins and leukotrienes also affect the migration and invasion of carcinoma cells. Our group has demonstrated that PGE₂ induces CRC cell migration and invasion through epidermal growth factor receptor (EGFR)–PI3K–Akt signalling *in vitro*⁶¹. Subsequently, we found that PGE₂ induction of an EP4–β-arrestin 1–SRC complex was crucial in transactivating EGFR to induce downstream Akt signalling and stimulate CRC cell migration *in vitro*, as well as the metastatic spread of disease to the liver *in vivo*⁶². The SRC–EGFR pathway also mediates PGE₂-induced human hepatocellular carcinoma cell invasion *in vitro*⁶³. These studies revealed that activation of PGE₂ receptors transactivates EGFR through an intracellular mechanism. It

has been reported that PGE₂ transactivation of EGFR depends on the extracellular release of an EGF-like ligand *in vitro*⁶⁴. PGE₂ can also induce cell migration and invasion through other signalling pathways, including the induction of matrix metalloproteinase 2 (MMP2) through an Erk–ETS1 cascade in pancreatic cancer cell lines⁶⁵ and the upregulation of C-C chemokine receptor 7 (CCR7) through EP2 and EP4 in breast cancer cell lines⁶⁶. In addition, treatment with an EP4 antagonist inhibits lung carcinoma cell migration and invasion *in vitro* and *in vivo*⁶⁷. Similar to PGE₂, PGF_{2α} also stimulates motility and invasion of colon⁶⁸ and endometrial⁶⁹ carcinoma cell lines and TXA₂ of prostate carcinoma cell lines⁷⁰. Relatively little is known about the ability of leukotrienes to regulate tumour cell migration and invasion. In an *in vivo* study, an LTB₄ antagonist was shown to inhibit the metastatic spread of pancreatic cancer cells to the liver and other organs⁷¹. In an *in vitro* study, LTD₄ induced non-transformed intestinal cell migration through the activation of a PI3K–Rac cascade⁷².

Solid tumours are thought to originate from a single replication-competent cell (stem cell or proliferative progenitor cell)¹. Recent studies have established that both prostaglandins and leukotrienes are central molecules in the regulation of stem cell homeostasis. PGE₂ protects mouse embryonic stem cells from undergoing apoptosis through an EP2–PI3K–Akt cascade⁷³ and regulates growth and development of both embryonic haematopoietic stem cells and adult stem cells in several different organisms^{74,75}. Similarly, LTB₄ and LTD₄ stimulate the proliferation of several types of stem and progenitor cells⁷⁶⁻⁷⁹. Collectively, the novel functions of these biologically active lipids on stem cell growth and maturation might suggest their ability to regulate cancer stem cell growth. This deserves considerable attention, and future research must be directed towards obtaining a better understanding of the role of prostaglandins and leukotrienes in regulating progenitor cells in solid tumours.

The role of eicosanoids in the inflammatory microenvironment

Chronic inflammation causes stromal cells to produce pro-inflammatory mediators, including eicosanoids, cytokines and chemokines, that shift the tissue microenvironment from normal to aberrant. In general, the inflammatory microenvironment, which is associated with changes in leukocyte profiles as well as their functionality, can initiate epithelial cell transformation and promote tumour growth, angiogenesis and metastasis⁸⁰. A growing body of evidence demonstrates that prostaglandins and leukotrienes are key immunomodulators mediating the crosstalk between epithelial cells and their surrounding stromal cells in the tumour microenvironment (FIG. 4).

The normal presence and trafficking of immune cells into the mucosal compartment has been termed physiological inflammation. In response to tumour-associated or chronic inflammation, transformed or normal epithelial cells and tissue-resident immune cells locally secrete cytokines, chemokines and pro-inflammatory eicosanoids that recruit additional leukocytes from the circulation into the tissue. The common pathological changes associated with chronic inflammation include increased infiltration of dysregulated immune cells, production of pro-inflammatory mediators, diminished epithelial integrity and deficient feedback systems that normally downregulate the mucosal response to antigens. Furthermore, the immune cells recruited to the tumour microenvironment are phenotypically different from the normal immune cells and can maintain inflammation and induce angiogenesis⁸⁰. For example, the massively recruited macrophages in the mucosa of active inflammatory bowel disease (IBD) are phenotypically different from normal macrophages and have a major role in chronic mucosal inflammation by secreting many pro-inflammatory cytokines⁸¹.

Although epidemiological and experimental evidence strongly implicates chronic inflammation as a risk factor for cancer, the mechanisms by which inflammation and inflammatory mediators result in neoplastic transformation and progression have not been

completely resolved. A strong association between chronic inflammation and malignant diseases occurs in CRC that arises in patients with IBD. The role of PGE₂ in IBD is the best characterized example of the role of prostaglandins in chronic inflammation. PGE₂ exacerbates inflammation and disease severity through increasing the infiltration of neutrophils and T helper 17 (T_H17) cells to the colonic tissue in a murine model of IBD⁸². Several lines of evidence further suggest that PGE₂-induced expansion of inflammatory T_H17 cells depends on the involvement of T cells and dendritic cells. PGE₂ shifts the interleukin-12 (IL-12)/IL-23 balance in dendritic cells through EP2 and EP4 receptors in favour of IL-23, which in turn increases the number of T_H17 cells *in vitro*⁸². IL-12 promotes T helper 1 (T_H1) responses and suppresses T_H17 development and function, whereas IL-23 is essential for T_H17 expansion and survival. PGE₂ also facilitates IL-23-induced T_H17 expansion from peripheral blood mononuclear cells and naive T cells *in vitro*^{83,84}, induces T_H1 cell differentiation *in vitro* and promotes inflammation through T_H1 and T_H17 cells in an animal model of chronic inflammation through the EP4 receptor⁸⁵. In addition, PGE₂ induces dendritic cell migration *in vitro* by upregulation of CCR7 (REF. ⁸⁶). By contrast, PGD₂ inhibits the migration of dendritic cells to the lymph nodes *in vivo*⁸⁷. During chronic inflammation, dendritic cells secrete large amounts of inflammatory cytokines that further recruit monocytes and immature dendritic cells into inflamed tissues.

Leukotrienes are powerful lipid mediators of inflammation in various acute and chronic inflammatory and allergic diseases, including IBD⁸⁸. In fact, urinary LTE₄ can serve as a biomarker for IBD⁸⁹. Similar to chemokines, LTB₄ is another potent chemoattractant and activator of neutrophils, eosinophils, basophils, T cells, dendritic cells and macrophages in inflammatory sites⁹⁰⁻⁹³; a Rac-Erk signalling cascade might also be responsible for LTB₄-induced chemotaxis⁹⁴. Similar to PGE₂, LTB₄ promotes the migration of dendritic cells through the upregulation of CCR7 *in vitro* and *in vivo*⁹⁵. However, it is not clear whether Rac-Erk signalling mediates LTB₄-induced CCR7 expression. Collectively, these studies show that pro-inflammatory prostaglandins and leukotrienes could stimulate tumour growth through establishing an inflammatory microenvironment.

The role of eicosanoids in tumour immunosuppression

It is well accepted that cooperative interactions between carcinoma cells and other cells in the tumour microenvironment contribute to cancer progression. Tumour epithelial cells secrete cytokines, chemokines and pro-inflammatory eicosanoids that recruit and reprogramme various pro-inflammatory leukocytes to establish an immunosuppressive tumour microenvironment. Of prostaglandins and leukotrienes, only PGE₂ has been shown to have a clear role in the regulation of tumour immunosuppression through T cells, CD8⁺ cytotoxic T cells, regulatory T cells, dendritic cells and myeloid-derived suppressor cells (MDSCs) (FIG. 5). PGE₂ helps to shift the tumour microenvironment from anti-tumour T_H1 responses to immunosuppressive T helper 2 (T_H2) responses by downregulation of T_H1 cytokines (tumour necrosis factor- α (TNF α), interferon- γ (IFN γ) and IL-2) and upregulation of T_H2 cytokines (IL-4, IL-10 and IL-6) in immune cells⁹⁶⁻⁹⁸. Moreover, PGE₂ directly inhibits the activity of cytotoxic T cells through the upregulation of a CD94 and NKG2A complex and induces regulatory T cell function *in vitro*^{99,100}. PGE₂ produced by tumour cells can also indirectly abolish the antitumour effects of cytotoxic T cells *in vivo* and *in vitro* through the downregulation of both direct antigen presentation by tumour cells and cross-presentation by dendritic cells¹⁰¹. For example, an *in vitro* study showed that PGE₂ switches the function of dendritic cells from induction of immunity to T cell tolerance through the upregulation of CD25 and indoleamine 2,3-dioxygenase¹⁰². In addition to modulating T cell and dendritic cell function, PGE₂ modulates cancer-associated immunosuppression through the inhibition of dendritic cell differentiation and T cell proliferation *in vivo*^{103,104}. Furthermore, PGE₂ promoted mammary tumour progression through the induction of MDSCs *in vivo*¹⁰⁵.

Collectively, the effects of PGE₂ on the immune system may allow neoplastic cells to evade attack. To our knowledge, there is nothing further reported in the literature indicating the participation of other prostaglandins and leukotrienes in cancer-associated immunosuppression.

Angiogenesis—It is widely recognized that angiogenesis is required for tumours to grow beyond a certain size and to metastasize. To develop a stable blood supply for tumour growth, many cells in the tumour microenvironment, including tumour epithelial cells, stromal cells and immune cells, secrete various proangiogenic factors that stimulate endothelial cell recruitment, proliferation, migration and tubule formation. Numerous *in vitro* and *in vivo* studies indicate that prostaglandins and leukotrienes modulate angiogenesis at different levels (FIG. 6).

Homozygous deletion of *Ep2* completely abrogates the induction of vascular endothelial growth factor (VEGF) in the intestinal polyp stroma of *Apc*^{Δ716} mice and inhibits intestinal polyp growth, demonstrating that PGE₂ induction of VEGF is important for tumour growth in this mouse model²⁹. Moreover, PGE₂ induced expression of CXCL1, a pro-angiogenic chemokine, in human CRC cells, and the release of CXCL1 from tumour epithelial cells in turn stimulated microvascular endothelial cell migration and tube formation *in vitro* and *in vivo*¹⁰⁶. Activation of EP2 receptors by PGE₂ induces FGF2 expression through potential multiple protein kinase A (PKA), SRC, EGFR, and ERK1 and ERK2 signalling pathways in an endometrial adenocarcinoma cell line and in endometrial adenocarcinoma tissue explants¹⁰⁷. PGE₂ released from mammary tumour epithelial cells induces angiogenesis through the induction of pro-angiogenic factors through a cyclic AMP-dependent PKA pathway *in vivo* and *in vitro*¹⁰⁸. PGE₂ can also induce VEGF secretion in ovarian, prostate and gastric cancer cell lines through the activation of EGFR downstream of EP2 and EP4 (REFS 109–111). Similar to PGE₂, PGF_{2α} induces VEGF expression through an FP–EGFR–Ras–Erk pathway in an endometrial adenocarcinoma cell line¹¹². Moreover, PGF_{2α}–FP signalling can stimulate the secretion of CXCL1 in endometrial tumour cells to promote neutrophil infiltration in mouse xenograft tumours¹¹³; neutrophil infiltration has also been shown to be essential for angiogenesis in other tumour models¹¹⁴. In tumour implantation models, increased TXA₂ levels as a result of overexpression of TXA₂ synthase in colon-26 adenocarcinoma cells accelerated tumour growth and tumour-associated angiogenesis in syngeneic BALB/c mice¹¹⁵.

In addition to inducing the production of angiogenic factors in epithelial cells, prostaglandin signalling in stromal cells also contributes to angiogenesis. A host PGE₂–EP2 signal is required for tumour angiogenesis by enhancing endothelial cell motility and vascular hyperpermeability in a mouse model of breast cancer¹¹⁶. Similarly, the host PGE₂–EP3 signal is a prerequisite for VEGF expression in the stroma and tumour angiogenesis in a mouse model of lung carcinoma¹¹⁷. In endothelial cells, PGE₂ not only upregulates VEGF and FGF2 expression through the stimulation of an ERK2–JUN N-terminal kinase 1 (JNK1) signalling pathway, which is important for inducing cell growth and survival¹¹⁸, but also promotes αVβ3 integrin-dependent migration and spreading of endothelial cells¹¹⁹ and mediates VEGF and FGF2-induced CXCR4-dependent neovessel assembly *in vivo*¹²⁰. In addition, TXA₂ mediates the effects of COX2 on endothelial cell migration and angiogenesis *in vitro* and *in vivo*¹²¹. Intriguingly, VEGF and FGF2 induce COX2, and subsequently PGE₂ and PGI₂, in endothelial cells, suggesting that the effects of PGE₂ on regulation of VEGF and FGF2 are probably amplified through a positive feedback loop¹²⁰. In contrast to PGE₂ signalling, deficiency of the DP receptor in the host accelerates tumour growth of implanted lung carcinomas by stimulating angiogenesis¹²², suggesting that the host PGD₂–DP signal inhibits tumour growth by inhibiting angiogenesis.

The physiological significance of leukotrienes in angiogenesis is much less well characterized than that of the prostaglandins. LTB₄ induced endothelial cell migration and tube formation *in vitro* and stimulated VEGF-induced angiogenesis through the BLT2 receptor *in vivo*¹²³. Similarly, LTC₄ induced endothelial cell proliferation *in vitro*¹²⁴ and LTC₄ and LTD₄ promoted angiogenesis in the chick chorioallantoic membrane system¹²⁵. In addition, LTB₄ enhances hypoxia-induced microvascular alterations *in vivo*¹²⁶.

In addition to the involvement of PGE₂ and leukotrienes in signalling crosstalk between tumour epithelial and endothelial cells, PGE₂ also stimulates immune cells to produce pro-angiogenic factors. For example, PGE₂ promotes mast cells to release VEGF and the chemokine CCL2 *in vitro*^{127,128}. CCL2 can induce tumour-associated angiogenesis¹²⁹ by directly recruiting endothelial cells that express its receptor CCR2 *in vitro* and *in vivo*¹³⁰, by inducing VEGF release from macrophages through a COX2-PGE₂ pathway *in vitro*¹³¹, and/or by indirectly attracting more tumour-associated monocytes and macrophages, which are phenotypically distinct from normal macrophages in their ability to promote angiogenesis in mice¹³². LTB₄ induces neutrophil-mediated vascular permeability *in vitro* and *in vivo*¹³³. Moreover, inhibition of CysLT production by the deletion of LTC₄ synthase reduces vascular permeability in zymosan A-induced, monocyte and macrophage-mediated peritoneal inflammation and in immunoglobulin E-dependent, mast cell-mediated passive cutaneous anaphylaxis¹³⁴, suggesting that CysLTs promote inflammation-mediated vascular permeability.

Therapeutic and chemopreventive agents

A retrospective cohort study shows that aspirin, a nonselective NSAID, specifically reduces cancer risk in the subgroup of patients whose colon tumours expressed higher levels of COX2 (REF. ¹³⁵). In addition to prevention, regular aspirin use after the diagnosis of CRC at stages I, II and III improves overall survival, especially among individuals whose tumours overexpress COX2 (REF. ¹³⁶). However, the prolonged use of non-selective NSAIDs is associated with adverse gastrointestinal side effects. Long-term use of high doses of selective COX2 inhibitors is currently not recommended because of the unacceptable cardiovascular side effects in certain patients, especially those with a history of atherosclerotic heart disease¹³⁷. However, a selective COX2 inhibitor (celecoxib) is still approved by the US Food and Drug Administration for use as an adjuvant treatment in patients at a high risk for developing CRC, such as those with familial adenomatous polyposis. It has been proposed that some of the adverse effects related to NSAID use are associated with a global reduction in prostanoid production¹³⁸. For instance, COX2 deficiency in mice contributes to the pro-atherogenic properties of high-density lipoprotein cholesterol, with increased lipid deposition in the aorta and the dramatic imbalance in circulating prostanoids¹³⁹. One hypothetical method to avoid the cardiovascular side effects of COX2 inhibition would be to target only COX-derived PGE₂ signalling that mediates the tumour-promoting effects of COX2. For example, antagonists of PGE₂ receptors have been developed and show promising effects for preventing and/or inhibiting growth of different types of tumours, including colon, oesophageal, lung and breast in preclinical animal models^{27-29,33,67,140}.

Inhibition of the 5-LOX pathway may also be useful for cancer therapy. For example, a 5-LOX inhibitor, zileuton, has been shown to prevent lung tumorigenesis in carcinogen-treated mice¹⁴¹. A combined treatment regimen using a selective COX2 inhibitor and a 5-LOX inhibitor not only had additive effects on reducing tumour growth in mouse xenograft models of human colon, oesophageal, breast and skin cancer¹⁴²⁻¹⁴⁵, but also reduced liver metastases in a hamster model of chemically induced ductal pancreatic adenocarcinoma¹⁴⁶. Moreover, blockage of leukotriene production by the LTA₄ hydrolase inhibitor bestatin reduced tumour burden in rats, as described above⁴². The LTB₄ receptor antagonist, LY293111, significantly inhibits tumour growth and metastases in a fluorescent orthotopic model of pancreatic

cancer⁷¹ and a mouse xenograft model of human CRC¹⁴⁷. Unfortunately, the results from two Phase II trials showed that LY293111 did not improve progressionfree survival in patients with non-small-cell lung or pancreatic cancer¹⁴⁸. In addition, a CysLT1 receptor antagonist, zafirlukast, reduced tumour burden in a mouse model of carcinogen-induced lung tumours¹⁴⁹. Although NSAIDs are still among the most promising chemopreventive agents for cancer, cardiovascular and gastrointestinal side effects have dampened enthusiasm for their use as chemopreventive agents. Therefore, it is now crucial to evaluate whether the antagonists of PGE₂ and leukotriene receptors have better specificity for human cancer prevention and treatment.

Summary

Many strategies exist to develop more effective cancer prevention and treatment options. Chemoprevention and targeted therapies are being carefully evaluated on several fronts as effective measures to achieve better cancer control. A big challenge remains to develop chemopreventive agents that are both effective and safe. An entirely new approach, referred to as personalized cancer prevention and treatment, is likely to have an important role in achieving these goals. This idea is supported by the observations that patients whose colon tumours express higher levels of COX2 benefit from regular aspirin use in cancer prevention and risk reduction^{135,136}, and that patients whose tumours express a mutant form of *KRAS* do not benefit from EGFR-specific therapy with cetuximab or panitumumab¹⁵⁰. However, this approach relies on a foundation of knowledge derived from the molecular basis of carcinogenesis to the molecular characterization of individual cancers. Understanding the role of eicosanoids in tumorigenesis and profiling these biologically active lipids in each patient are two crucial steps towards this personalized approach as they may be biomarkers for predicting which patients respond to NSAIDs in prevention and/or as intermediate markers for assessing response during treatment.

In addition to biomarkers, certain eicosanoids are also potential drug targets for personalizing cancer prevention and/or treatment. The evidence that proinflammatory eicosanoids such as PGE₂, LTB₄ and LTD₄ promote tumour growth and metastasis, whereas anti-inflammatory PGD₂ suppresses tumour growth will provide a rationale to develop the next generation of personalized cancer preventive agents. Therefore, it is now crucial to evaluate whether these prostaglandin and leukotriene receptor antagonists and agonists, as well as agents that lower cellular levels of pro-inflammatory prostaglandins and leukotrienes, have better efficacy with fewer adverse effects than NSAIDs. For example, the activators of 15-PGDH and inhibitors of PGE₂ synthases, LTA₄ hydrolase and LTC₄ synthases may be useful agents for future studies.

Acknowledgments

This work is partly supported by the US National Institutes of Health Grants RO1DK 62112, P01-CA-77839, R37-DK47297 and P30 DK-58404 (R.N.D.). R.N.D. (R37-DK47297) is recipient of an NIH MERIT award. We also thank the National Colorectal Cancer Research Alliance (NCCRA) for generous support (R.N.D.). We also kindly thank D. Menter for his assistance in the preparation of figures.

Glossary

Cysteinyl leukotriene (CysLT)	Leukotriene that contains the amino acid cysteine conjugated to the lipid backbone.
<i>Apc</i> ^{Min/+} mice	Carry a point mutation in one <i>Apc</i> allele and spontaneously develop intestinal adenomas. Used as a model for human familial adenomatous polyposis and for human sporadic colorectal cancer.

Azoxymethane (AOM) mouse model	One of the chemically induced colorectal cancer models in which mice are exposed to a chemical carcinogen, AOM.
T helper 17 (T _H 17) cells	A functional subset of CD4 ⁺ T helper cells that secrete particular inflammatory cytokines, including interleukin-17, which mediate pathogenic responses in autoimmune diseases.
Dendritic cells	Bone marrow-derived immune accessory cells that function as antigen-presenting cells for naive T cells and that lead to the initiation of adaptive immune responses to protein antigens.
Cytotoxic T cells	A subgroup of T cells (also known as CD8 ⁺ T cells or killer T cells) that are capable of recognizing and inducing the death of infected somatic or tumour cells. CD8 ⁺ T cells are recognized as cytotoxic T cells once they become activated.
Regulatory T cells	A T cell subpopulation that suppresses activation of other T cells and maintains immune system homeostasis and peripheral tolerance to self-antigens.
Myeloid-derived suppressor cells (MDSCs)	Immature myeloid cells with potent immunosuppressive functions.
Cross-presentation	A mechanism by which a professional antigen-presenting cell takes up, processes and presents extracellular antigens from a third cell (for example, a virus-infected or tumour cell) with major histocompatibility complex class I molecules to activate a naive CD8 ⁺ T cell.
T cell tolerance	Unresponsiveness of the adaptive immune system to antigens, as a result of the inactivation or death of antigen-specific T cells, which is induced by exposure to the antigens.
<i>Apc</i> ^{Δ716} mice	Generated by inserting neomycin into exon 15 of <i>Apc</i> , which results in truncated APC at codon 716. Spontaneously develop intestinal adenomas and are another model for human familial adenomatous polyposis and sporadic colorectal cancer.
Chick chorioallantoic membrane system	A biological assay using the well-vascularized chorioallantoic membrane of the chicken egg to evaluate the biological activity of pro-angiogenic and anti-angiogenic factors.

References

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nature Med* 2004;10:789–799. [PubMed: 15286780]
2. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome — components and functional correlates. *Genes Dev* 2006;20:3215–3231. [PubMed: 17158741]
3. Woutersen RA, Appel MJ, van Garderen-Hoetmer A, Wijnands MV. Dietary fat and carcinogenesis. *Mutat. Res* 1999;443:111–127. [PubMed: 10415435]
4. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. *Inflammopharmacology* 2009;17:55–67. [PubMed: 19340409]
5. Pidgeon GP, et al. Lipoxygenase metabolism: roles in tumor progression and survival. *Cancer Metastasis Rev* 2007;26:503–524. [PubMed: 17943411]
6. Dubois RN, et al. Cyclooxygenase in biology and disease. *FASEB J* 1998;12:1063–1073. [PubMed: 9737710]

7. Eberhart CE, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. *Gastroenterology* 1994;107:1183–1188. [PubMed: 7926468] This study was the first to report that COX2 expression is increased in human CRC.
8. de Groot DJ, de Vries EG, Groen HJ, de Jong S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. *Crit. Rev. Oncol. Hematol* 2007;61:52–69. [PubMed: 16945549]
9. Gupta RA, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. *Cancer Res* 2003;63:906–911. [PubMed: 12615701]
10. Wang D, et al. Prostaglandin E₂ promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. *Cancer Cell* 2004;6:285–295. [PubMed: 15380519] This report was the first to indicate crosstalk between PGE₂ signalling and Wnt signalling in promoting colon tumour growth.
11. Wang D, DuBois RN. Measurement of eicosanoids in cancer tissues. *Methods Enzymol* 2007;433:27–50. [PubMed: 17954227]
12. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to *in vivo* tissue responses. *Pharmacol. Rev* 2006;58:375–388. [PubMed: 16968946]
13. Zarini S, Gijon MA, Ransome AE, Murphy RC, Sala A. Transcellular biosynthesis of cysteinyl leukotrienes *in vivo* during mouse peritoneal inflammation. *Proc. Natl Acad. Sci. USA* 2009;106:8296–8301. [PubMed: 19416808]
14. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. *J. Lab. Clin. Med* 1993;122:518–523. [PubMed: 8228569]
15. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. *Semin. Oncol* 2004;31:64–73. [PubMed: 15052544]
16. McLemore TL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. *Cancer Res* 1988;48:3140–3147. [PubMed: 3130187]
17. Hambek M, et al. Inverse correlation between serum PGE₂ and T classification in head and neck cancer. *Head Neck* 2007;29:244–248. [PubMed: 17123309]
18. Backlund MG, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. *J. Biol. Chem* 2005;280:3217–3223. [PubMed: 15542609]
19. Wolf I, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. *Cancer Res* 2006;66:7818–7823. [PubMed: 16885386]
20. Hughes D, et al. NAD⁺-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. *Cancer Prev. Res. (Phila Pa)* 2008;1:241–249. [PubMed: 19138967]
21. Thiel A, et al. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. *Clin. Cancer Res* 2009;15:4572–4580. [PubMed: 19584167]
22. Hansen-Petrik MB, et al. Prostaglandin E₂ protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc^{Min/+} mice. *Cancer Res* 2002;62:403–408. [PubMed: 11809688]
23. Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. *Proc. Natl Acad. Sci. USA* 2009;106:9409–9413. [PubMed: 19470469]
24. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E₂ administration. *Carcinogenesis* 2003;24:985–990. [PubMed: 12771044]
25. Myung SJ, et al. 15-Hydroxyprostaglandin dehydrogenase is an *in vivo* suppressor of colon tumorigenesis. *Proc. Natl Acad. Sci. USA* 2006;103:12098–12102. [PubMed: 16880406]
26. Nakanishi M, et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. *Cancer Res* 2008;68:3251–3259. [PubMed: 18451151]
27. Watanabe K, et al. Role of the prostaglandin E receptor subtype EP₁ in colon carcinogenesis. *Cancer Res* 1999;59:5093–5096. [PubMed: 10537280]
28. Mutoh M, et al. Involvement of prostaglandin E receptor subtype EP₄ in colon carcinogenesis. *Cancer Res* 2002;62:28–32. [PubMed: 11782353]

29. Sonoshita M, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in *Apc^{d716}* knockout mice. *Nature Med* 2001;7:1048–1051. [PubMed: 11533709] This report was first to indicate that PGE₂ signalling promotes tumour-associated angiogenesis *in vivo*.
30. Oshima H, et al. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. *Gastroenterology* 2006;131:1086–1095. [PubMed: 17030179]
31. Keith RL, et al. Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. *Anticancer Res* 2006;26:2857–2861. [PubMed: 16886605]
32. Chang SH, Ai Y, Breyer RM, Lane TF, Hla T. The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. *Cancer Res* 2005;65:4496–4499. [PubMed: 15930264]
33. Kawamori T, et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP₁ antagonist, on breast cancer development. *Carcinogenesis* 2001;22:2001–2004. [PubMed: 11751431]
34. Park JM, et al. Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in *Apc^{Min/+}* mice. *Cancer Res* 2007;67:881–889. [PubMed: 17283118]
35. Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. *J. Cell Physiol* 2007;212:1–12. [PubMed: 17443682]
36. Wolffe D. Enhancement of carcinogen-induced malignant cell transformation by prostaglandin F_{2α}. *Toxicology* 2003;188:139–147. [PubMed: 12767686]
37. Wang D, et al. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. *Proc. Natl Acad. Sci. USA* 2006;103:19069–19074. [PubMed: 17148604]
38. Larre S, et al. PGE₂ and LTB₄ tissue levels in benign and cancerous prostates. *Prostaglandins Other Lipid Mediat* 2008;87:14–19. [PubMed: 18577464]
39. Dreyling KW, et al. Leukotriene synthesis by human gastrointestinal tissues. *Biochim. Biophys. Acta* 1986;878:184–193. [PubMed: 3019409]
40. Hennig R, et al. 5-Lipoxygenase and leukotriene B₄ receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. *Am. J. Pathol* 2002;161:421–428. [PubMed: 12163367]
41. Yoo MH, Song H, Woo CH, Kim H, Kim JH. Role of the BLT2, a leukotriene B₄ receptor, in Ras transformation. *Oncogene* 2004;23:9259–9268. [PubMed: 15489890]
42. Chen X, et al. Leukotriene A₄ hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. *J. Natl Cancer Inst* 2003;95:1053–1061. [PubMed: 12865451]
43. Ohd JF, et al. Expression of the leukotriene D₄ receptor CysLT₁, COX-2, and other cell survival factors in colorectal adenocarcinomas. *Gastroenterology* 2003;124:57–70. [PubMed: 12512030]
44. Matsuyama M, et al. Overexpression of cysteinyl LT₁ receptor in prostate cancer and CysLT₁R antagonist inhibits prostate cancer cell growth through apoptosis. *Oncol. Rep* 2007;18:99–104. [PubMed: 17549353]
45. Magnusson C, Ehrnstrom R, Olsen J, Sjolander A. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. *Cancer Res* 2007;67:9190–9198. [PubMed: 17909024]
46. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. *Cancer Res* 2005;65:1822–1829. [PubMed: 15753380]
47. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E₂ promotes colon cancer cell growth through a G_s-axin- β -catenin signaling axis. *Science* 2005;310:1504–1510. [PubMed: 16293724] This report was the first to show that PGE₂ activates Wnt signalling by the disruption of a β -catenin inhibitory complex.
48. Krysan K, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. *Cancer Res* 2005;65:6275–6281. [PubMed: 16024629]
49. Zhou J, et al. Interactions between prostaglandin E₂, liver receptor homologue-1, and aromatase in breast cancer. *Cancer Res* 2005;65:657–663. [PubMed: 15695411]

50. Sheng H, Shao J, Morrow J, Beauchamp RD, DuBois RN. Modulation of apoptosis by prostaglandin treatment in human colon cancer cells. *Cancer Res* 1998;58:362–366. [PubMed: 9443418]
51. Poligone B, Baldwin AS. Positive and negative regulation of NF- κ B by COX-2: roles of different prostaglandins. *J. Biol. Chem* 2001;276:38658–38664. [PubMed: 11509575]
52. Sales KJ, Boddy SC, Williams AR, Anderson RA, Jabbour HN. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. *Endocrinology* 2007;148:3635–3644. [PubMed: 17478553]
53. Kim J, et al. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. *Cancer Res* 2005;65:6189–6198. [PubMed: 16024620]
54. Jeong CH, et al. [6]-gingerol suppresses colon cancer growth by targeting leukotriene A₄ hydrolase. *Cancer Res* 2009;69:5584–5591. [PubMed: 19531649]
55. Ihara A, et al. Blockade of leukotriene B₄ signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. *J. Pharmacol. Sci* 2007;103:24–32. [PubMed: 17220595]
56. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE. LTB₄ stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. *Biochem. Biophys. Res. Commun* 2005;335:949–956. [PubMed: 16105664]
57. Mezhybovska M, Wikstrom K, Ohd JF, Sjolander A. The inflammatory mediator leukotriene D₄ induces β -catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells. *J. Biol. Chem* 2006;281:6776–6784. [PubMed: 16407243]
58. Paruchuri S, Hallberg B, Juhas M, Larsson C, Sjolander A. Leukotriene D₄ activates MAPK through a Ras-independent but PKC ϵ -dependent pathway in intestinal epithelial cells. *J. Cell Sci* 2002;115:1883–1893. [PubMed: 11956320]
59. Ohd JF, Wikstrom K, Sjolander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. *Gastroenterology* 2000;119:1007–1018. [PubMed: 11040187]
60. Paruchuri S, Mezhybovska M, Juhas M, Sjolander A. Endogenous production of leukotriene D₄ mediates autocrine survival and proliferation via CysLT₁ receptor signalling in intestinal epithelial cells. *Oncogene* 2006;25:6660–6665. [PubMed: 16715140]
61. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E₂ regulates cell migration via the intracellular activation of the epidermal growth factor receptor. *J. Biol. Chem* 2003;278:35451–35457. [PubMed: 12824187]
62. Buchanan FG, et al. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. *Proc. Natl Acad. Sci. USA* 2006;103:1492–1497. [PubMed: 16432186] This study was the first to report a link between PGE signalling and the metastatic spread of colon tumour cells to the liver *in vivo*.
63. Han C, Michalopoulos GK, Wu T. Prostaglandin E₂ receptor EP₁ transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. *J. Cell Physiol* 2006;207:261–270. [PubMed: 16331686]
64. Pai R, et al. Prostaglandin E₂ transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. *Nature Med* 2002;8:289–293. [PubMed: 11875501]
65. Ito H, et al. Prostaglandin E₂ enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. *Cancer Res* 2004;64:7439–7446. [PubMed: 15492268]
66. Pan MR, Hou MF, Chang HC, Hung WC. Cyclooxygenase-2 up-regulates CCR7 via EP₂/EP₄ receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. *J. Biol. Chem* 2008;283:11155–11163. [PubMed: 18319253]
67. Yang L, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP₄ receptor antagonism. *Cancer Res* 2006;66:9665–9672. [PubMed: 17018624]
68. Qualtrough D, et al. Prostaglandin F_{2 α} stimulates motility and invasion in colorectal tumor cells. *Int. J. Cancer* 2007;121:734–740. [PubMed: 17437271]
69. Sales KJ, Boddy SC, Jabbour HN. F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. *Oncogene* 2008;27:2466–2477. [PubMed: 17968320]
70. Nie D, et al. Thromboxane A₂ receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. *Cancer Res* 2008;68:115–121. [PubMed: 18172303]
71. Hennig R, et al. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. *Neoplasia* 2005;7:417–425. [PubMed: 15967119]

72. Paruchuri S, Broom O, Dib K, Sjolander A. The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. *J. Biol. Chem* 2005;280:13538–13544. [PubMed: 15657050]
73. Liou JY, et al. Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. *Stem Cells* 2007;25:1096–1103. [PubMed: 17234991]
74. North TE, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. *Nature* 2007;447:1007–1011. [PubMed: 17581586] This paper describes the first evidence that PGE₂ can regulate stem and progenitor cell homeostasis.
75. Goessling W, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. *Cell* 2009;136:1136–1147. [PubMed: 19303855]
76. Wada K, et al. Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. *FASEB J* 2006;20:1785–1792. [PubMed: 16940150]
77. Chung JW, et al. Leukotriene B4 pathway regulates the fate of the hematopoietic stem cells. *Exp. Mol. Med* 2005;37:45–50. [PubMed: 15761251]
78. Boehmler AM, et al. The CysLT1 ligand leukotriene D4 supports α 4 β 1- and α 5 β 1-mediated adhesion and proliferation of CD34⁺ hematopoietic progenitor cells. *J. Immunol* 2009;182:6789–6798. [PubMed: 19454674]
79. Braccioni F, et al. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. *J. Allergy Clin. Immunol* 2002;110:96–101. [PubMed: 12110827]
80. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albin A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. *Cancer Metastasis Rev* 2008;27:31–40. [PubMed: 18087678]
81. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. *Inflamm. Bowel Dis* 2000;6:21–33. [PubMed: 10701146]
82. Shebanie AF, et al. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-IL-17 axis. *J. Immunol* 2007;178:8138–8147. [PubMed: 17548652] This was the first study that offered direct evidence that PGE₂ treatment exacerbates inflammation and disease severity in a mouse model of IBD.
83. Chizzolini C, et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. *Blood* 2008;112:3696–3703. [PubMed: 18698005]
84. Boniface K, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. *J. Exp. Med* 2009;206:535–548. [PubMed: 19273625]
85. Yao C, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. *Nature Med* 2009;15:633–640. [PubMed: 19465928] This paper showed the first *in vivo* evidence that EP4 mediates the effects of PGE₂ on promoting chronic inflammation.
86. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. *Blood* 2002;100:1354–1361. [PubMed: 12149218]
87. Angeli V, et al. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. *J. Exp. Med* 2001;193:1135–1147. [PubMed: 11369785]
88. Henderson WR Jr. The role of leukotrienes in inflammation. *Ann. Intern. Med* 1994;121:684–697. [PubMed: 7944079]
89. Stanke-Labesque F, Pofelski J, Moreau-Gaudry A, Bessard G, Bonaz B. Urinary leukotriene E4 excretion: a biomarker of inflammatory bowel disease activity. *Inflamm Bowel Dis* 2008;14:769–774. [PubMed: 18286646]
90. Bomalaski JS, Dundee D, Brophy L, Clark MA. Leukotriene B4 modulates phospholipid methylation and chemotaxis in human polymorphonuclear leukocytes. *J. Leukoc. Biol* 1990;47:1–12. [PubMed: 2152937]
91. Islam SA, et al. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. *Blood* 2006;107:444–453. [PubMed: 16179368]

92. Shin EH, Lee HY, Bae YS. Leukotriene B₄ stimulates human monocyte-derived dendritic cell chemotaxis. *Biochem. Biophys. Res. Commun* 2006;348:606–611. [PubMed: 16889750]
93. Haribabu B, et al. Targeted disruption of the leukotriene B₄ receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. *J. Exp. Med* 2000;192:433–438. [PubMed: 10934231]
94. Woo CH, et al. Leukotriene B₄ stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. *J. Biol. Chem* 2002;277:8572–8578. [PubMed: 11756405]
95. Del Prete A, et al. Regulation of dendritic cell migration and adaptive immune response by leukotriene B₄ receptors: a role for LTB₄ in up-regulation of CCR7 expression and function. *Blood* 2007;109:626–631. [PubMed: 16985179]
96. Snijdewint FG, Kalinski P, Wierenga EA, Bos JD, Kapsenberg ML. Prostaglandin E₂ differentially modulates cytokine secretion profiles of human T helper lymphocytes. *J. Immunol* 1993;150:5321–5329. [PubMed: 8390534]
97. Huang M, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. *Cancer Res* 1998;58:1208–1216. [PubMed: 9515807]
98. Stolina M, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. *J. Immunol* 2000;164:361–370. [PubMed: 10605031]
99. Zeddou M, et al. Prostaglandin E₂ induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8⁺ T lymphocytes by a cAMP-dependent protein kinase A type I pathway. *Biochem. Pharmacol* 2005;70:714–724. [PubMed: 15978547]
100. Baratelli F, et al. Prostaglandin E₂ induces FOXP3 gene expression and T regulatory cell function in human CD4⁺ T cells. *J. Immunol* 2005;175:1483–1490. [PubMed: 16034085]
101. Ahmadi M, Emery DC, Morgan DJ. Prevention of both direct and cross-priming of antitumor CD8⁺ T-cell responses following overproduction of prostaglandin E₂ by tumor cells *in vivo*. *Cancer Res* 2008;68:7520–7529. [PubMed: 18794140]
102. von Bergwelt-Baildon MS, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E₂ and expressed by tumor-associated dendritic cells *in vivo*: additional mechanisms of T-cell inhibition. *Blood* 2006;108:228–237. [PubMed: 16522817]
103. Yang L, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. *J. Clin. Invest* 2003;111:727–735. [PubMed: 12618527] This study reported the first *in vivo* evidence that PGE₂ is a mediator of cancer-associated immunodeficiency.
104. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. *J. Clin. Immunol* 1983;3:295–315. [PubMed: 6140268]
105. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E₂ promotes tumor progression by inducing myeloid-derived suppressor cells. *Cancer Res* 2007;67:4507–4513. [PubMed: 17483367]
106. Wang D, et al. CXCL1 induced by prostaglandin E₂ promotes angiogenesis in colorectal cancer. *J. Exp. Med* 2006;203:941–951. [PubMed: 16567391]
107. Battersby S, et al. Seminal plasma and prostaglandin E₂ up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway. *Hum. Reprod* 2007;22:36–44. [PubMed: 16905765]
108. Chang SH, et al. Role of prostaglandin E₂-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. *Proc. Natl Acad. Sci. USA* 2004;101:591–596. [PubMed: 14688410]
109. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1-induced prostaglandin E₂-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. *J. Biol. Chem* 2004;279:46700–46705. [PubMed: 15347673]
110. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E₂ regulates tumor angiogenesis in prostate cancer. *Cancer Res* 2008;68:7750–7759. [PubMed: 18829529]
111. Ding YB, et al. PGE₂ up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system. *Exp. Oncol* 2005;27:108–113. [PubMed: 15995627]

112. Sales KJ, et al. A novel angiogenic role for prostaglandin F2 α -FP receptor interaction in human endometrial adenocarcinomas. *Cancer Res* 2005;65:7707–7716. [PubMed: 16140938]
113. Wallace AE, et al. Prostaglandin F2 α -F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. *Cancer Res* 2009;69:5726–5733. [PubMed: 19549892]
114. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. *Proc. Natl Acad. Sci. USA* 2006;103:12493–12498. [PubMed: 16891410]
115. Pradono P, et al. Gene transfer of thromboxane A₂ synthase and prostaglandin I₂ synthase antithetically altered tumor angiogenesis and tumor growth. *Cancer Res* 2002;62:63–66. [PubMed: 11782360]
116. Kamiyama M, et al. EP2, a receptor for PGE₂, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. *Oncogene* 2006;25:7019–7028. [PubMed: 16732324]
117. Amano H, et al. Host prostaglandin E₂-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. *J. Exp. Med* 2003;197:221–232. [PubMed: 12538661]
118. Pai R, et al. PGE₂ stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. *Biochem. Biophys. Res. Commun* 2001;286:923–928. [PubMed: 11527387]
119. Dormond O, Bezzi M, Mariotti A, Ruegg C. Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. *J. Biol. Chem* 2002;277:45838–45846. [PubMed: 12237321]
120. Salcedo R, et al. Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. *Blood* 2003;102:1966–1977. [PubMed: 12791666]
121. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. *Cancer Res* 1999;59:4574–4577. [PubMed: 10493510]
122. Murata T, et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis *in vivo*. *Proc. Natl Acad. Sci. USA* 2008;105:20009–20014. [PubMed: 19060214] This was the first report to show that PGD₂–DP signalling inhibits tumour-associated angiogenesis and tumour growth *in vivo*.
123. Kim GY, Lee JW, Cho SH, Seo JM, Kim JH. Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis. *Arterioscler Thromb. Vasc. Biol* 2009;29:915–920. [PubMed: 19286633]
124. Modat G, Muller A, Mary A, Gregoire C, Bonne C. Differential effects of leukotrienes B4 and C4 on bovine aortic endothelial cell proliferation *in vitro*. *Prostaglandins* 1987;33:531–538. [PubMed: 3037607]
125. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Leukotrienes C4 and D4 promote angiogenesis via a receptor-mediated interaction. *Eur. J. Pharmacol* 1994;258:151–154. [PubMed: 7523148]
126. Steiner DR, Gonzalez NC, Wood JG. Leukotriene B₄ promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. *J. Appl. Physiol* 2001;91:1160–1167. [PubMed: 11509511]
127. Abdel-Majid RM, Marshall JS. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. *J. Immunol* 2004;172:1227–1236. [PubMed: 14707101]
128. Nakayama T, Mutsuga N, Yao L, Tosato G. Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. *J. Leukoc. Biol* 2006;79:95–104. [PubMed: 16275896]
129. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. *Cancer Lett* 2008;267:271–285. [PubMed: 18439751]
130. Salcedo R, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. *Blood* 2000;96:34–40. [PubMed: 10891427]
131. Tanaka S, et al. Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. *Gut* 2006;55:54–61. [PubMed: 16085694]
132. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. *Cancer Res* 2007;67:5064–5066. [PubMed: 17545580]

133. Rosengren S, Olofsson AM, von Andrian UH, Lundgren-Akerlund E, Arfors KE. Leukotriene B₄-induced neutrophil-mediated endothelial leakage *in vitro* and *in vivo*. *J. Appl. Physiol* 1991;71:1322–1330. [PubMed: 1661722]
134. Kanaoka Y, Maekawa A, Penrose JF, Austen KF, Lam BK. Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C₄ synthase. *J. Biol. Chem* 2001;276:22608–22613. [PubMed: 11319240]
135. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. *N. Engl. J. Med* 2007;356:2131–2142. [PubMed: 17522398] This paper reported the first clinical evidence that aspirin seems to reduce the risk of CRCs that overexpress COX2 but not the risk of CRCs with weak or absent expression of COX2.
136. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. *JAMA* 2009;302:649–658. [PubMed: 19671906] This paper was the first to provide clinical evidence that aspirin can be used to treat advanced CRC.
137. Cuzick J, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. *Lancet Oncol* 2009;10:501–507. [PubMed: 19410194]
138. Fitzgerald GA. Coxibs and cardiovascular disease. *N. Engl. J. Med* 2004;351:1709–1711. [PubMed: 15470192]
139. Narasimha A, et al. A novel anti-atherogenic role for COX-2 — potential mechanism for the cardiovascular side effects of COX-2 inhibitors. *Prostaglandins Other Lipid Mediat* 2007;84:24–33. [PubMed: 17643885]
140. Piazzuelo E, et al. Effects of selective PGE₂ receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. *Prostaglandins Other Lipid Mediat* 2006;81:150–161. [PubMed: 17085323]
141. Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. *Carcinogenesis* 1998;19:1393–1400. [PubMed: 9744535]
142. Barry M, et al. Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer. *Ir. J. Med. Sci* 2009;178:201–208. [PubMed: 19340516]
143. Fegn L, Wang Z. Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. *J. Laryngol. Otol* 2009;123:880–884. [PubMed: 19216818]
144. Ye YN, et al. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. *Carcinogenesis* 2005;26:827–834. [PubMed: 15637091]
145. Chen X, et al. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. *Clin. Cancer Res* 2004;10:6703–6709. [PubMed: 15475461]
146. Wenger FA, et al. Effects of Celebrex and Zylflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. *Clin. Exp. Metastasis* 2002;19:681–687. [PubMed: 12553373]
147. Hennig R, et al. Effect of LY293111 in combination with gemcitabine in colonic cancer. *Cancer Lett* 2004;210:41–46. [PubMed: 15172119]
148. Adrian TE, Hennig R, Friess H, Ding X. The role of PPAR γ receptors and leukotriene B₄ receptors in mediating the effects of LY293111 in pancreatic cancer. *PPAR Res.* Jan 27;2009 doi: 10.1155/2008/827096.
149. Gunning WT, Kramer PM, Steele VE, Pereira MA. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. *Cancer Res* 2002;62:4199–4201. [PubMed: 12154018]
150. Monzon FA, et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. *Arch. Pathol. Lab. Med* 2009;133:1600–1606. [PubMed: 19792050]




Figure 1. An overview of eicosanoid synthesis pathways

Arachidonic acid is a polyunsaturated fatty acid that constitutes the phospholipid domain of most cell membranes and is liberated from the cellular membranes by cytoplasmic phospholipase A2 (PLA2). Free arachidonic acid can be metabolized to eicosanoids through three major pathways: the cyclooxygenase (COX), the lipoxygenase (LOX) and the cytochrome P450 monooxygenase pathways. In the COX pathway, the key step is the enzymatic conversion of arachidonic acid to the intermediate prostaglandin G₂ (PGG₂), which is then reduced to an intermediate PGH₂ by the peroxidase activity of COX. PGH₂ is sequentially metabolized to prostanoids, including prostaglandins (PGs) and thromboxanes (TXs) by specific prostaglandin and thromboxane synthases. LOXs convert arachidonic acid into biologically active metabolites such as leukotrienes and hydroxyeicosatetraenoic acids (HETEs); P450 metabolizes arachidonic acid into epoxyeicosatrienoic acids (EETs), HETEs and hydroperoxyeicosatetraenoic acids (HPETEs). In the 5-LOX pathway, arachidonic acid is converted to an intermediary 5-HPETE, which is further metabolized to form the unstable leukotriene A₄ (LTA₄). LTA₄ is subsequently converted to 5-HETE, LTB₄, LTC₄, LTD₄ and LTE₄. Each of the prostaglandins and leukotrienes exerts its biological effects by binding to its cognate G protein-coupled receptor. PGI₂ can transactivate the nuclear peroxisome proliferator-activated receptor-δ (PPARδ), and a PGD₂ dehydration product, 15dPGJ₂, is a natural ligand for PPARγ. The multidrug resistance-associated protein (MRP) gene family is comprised of efflux transporters for both prostaglandins and leukotrienes, and PGT is an influx transporter for prostaglandins. Hydroxyprostaglandin dehydrogenase 15-(NAD) (15-PGDH) mainly metabolizes intracellular PGE₂ and PGF_{2α} to a stable 13,14-dihydro-15-keto-PGE₂ and 13,14-dihydro-15-keto-PGF_{2α}. The red boxes indicate the signalling pathways that are discussed in this Review. CysLT, cysteinyl leukotriene; NSAID, non-steroidal anti-inflammatory drug.




Figure 2. Models of pro-inflammatory prostaglandins and leukotrienes in promoting cancer progression

Following the initiation of epithelial tumours, the reciprocal interactions between transformed epithelial and stromal cells have a key role in facilitating cancer progression. Pro-inflammatory prostaglandins and leukotrienes produced by tumour epithelial cells and their surrounding stromal cells are key mediators in this crosstalk and can accelerate tumour growth and metastasis through several methods. First, the pro-inflammatory prostaglandins (PGs) and leukotrienes (LTs) can directly induce epithelial tumour cell proliferation, survival, and migration and invasion in autocrine and paracrine manners. These pro-inflammatory lipids also stimulate epithelial cells and their surrounding stromal cells to produce growth factors, pro-inflammatory mediators and angiogenic factors, which switch the microenvironment from normal to tumour supporting. The tumour microenvironment, in turn, recruits immune cells and endothelial cells (tumour-infiltrating cells), which produce more pro-inflammatory mediators including eicosanoids, growth factors and angiogenic factors. These factors accelerate tumour growth and stimulate metastasis through an autocrine loop by inducing angiogenesis and evading attack by the immune system.




Figure 3. PGE₂ and LTB₄ promote cancer progression through the induction of tumour epithelial cell proliferation, survival, and migration and invasion

Multiple cellular signalling pathways mediate the effects of prostaglandin E₂ (PGE₂) and leukotriene B₄ (LTB₄) on the regulation of epithelial tumour cell proliferation, survival, and migration and invasion. PGE₂ stimulates cell proliferation through multiple cascades in both colorectal cancer (CRC) and non-small-cell lung cancer cells. PGE₂ also induces cell proliferation through a glycogen synthase kinase-3β (GSK3β)–β-catenin (β-cat) pathway in CRC cells or by the upregulation of aromatase in breast cancer cells. PGE₂ inhibition of GSK3β reduces β-catenin phosphorylation and thereby prevents its degradation, leading to accumulation, nuclear translocation and functional activity of β-catenin. PGE₂ promotes CRC cell survival by activating a PI3K–Akt– peroxisome proliferator-activated receptor-δ (PPARδ) cascade *in vitro* and *in vivo*. In addition, PGE₂ induces CRC cell migration and invasion through β-arrestin-1–SRC–epidermal growth factor receptor (EGFR)–PI3K–Akt signalling *in vitro* and *in vivo*. PGE₂ transactivation of EGFR also depends on the extracellular release of an EGF-like ligand in CRC cell lines and a normal gastric epithelial cell line. PGE₂ also induces cell migration and invasion through an Erk–ETS1–matrix metalloproteinase 2 (MMP2) cascade in pancreatic cancer cell lines or through the upregulation of C-C chemokine receptor 7 (CCR7) in breast cancer cell lines. LTB₄ stimulates cell proliferation and promotes cell survival through a BLT1–Erk pathway in CRC cell lines or through both Mek–Erk and PI3K–Akt pathways in human pancreatic cancer cell lines. P, phosphorylation.




Figure 4. Prostaglandins and leukotrienes are key pro-inflammatory mediators in orchestrating crosstalk between tumour epithelial cells and immune cells

During the initiation of epithelial tumours or chronic inflammation, transformed or normal epithelial cells and tissue-resident immune cells locally secrete pro-inflammatory prostaglandins and leukotrienes such as prostaglandin E₂ (PGE₂) and leukotriene B₄ (LTB₄), which recruit large numbers of immune cells from the circulation into the mucosa and reprogramme the immune cells into pro-inflammatory leukocytes. For example, PGE₂ induces expansion of inflammatory T helper 17 (T_H17) cells by regulating interactions between T cells and dendritic cells and facilitates T_H1 differentiation. PGE₂ shifts the interleukin-12 (IL-12)/IL-23 balance in favour of IL-23 through the induction of IL-23 and inhibition of IL-12 expression in dendritic cells. IL-23 is essential for T_H17 expansion and survival, whereas IL-12 suppresses T_H17 development and function. In recruitment of immune cells, PGE₂ induces infiltration of neutrophils and T_H17 cells and enhances dendritic cell migration whereas PGD₂ inhibits dendritic cell migration. LTB₄ has a major role in attracting neutrophils, T cells, dendritic cells and macrophages from the circulation into inflammatory sites. Collectively, PGE₂ and LTB₄ induce the massive infiltration of immune cells and change their functionality, which in turn results in the establishment of a chronic inflammatory microenvironment.




Figure 5. PGE₂ provides coordinated regulation of tumour immunosuppression

Pro-inflammatory prostaglandin E² (PGE₂) produced by tumour epithelial cells and/or their surrounding stromal cells induces immunosuppression through several ways, including: downregulating anti-tumour T helper 1 (T_H1) cytokines and upregulating immunosuppressive T_H2 cytokines; inhibiting CD8⁺ T cell proliferation and activity, suppressing the anti-tumour activity of natural killer cells and stimulating the expansion of regulatory T cells (T_{Reg} cells) and myeloid-derived suppressor cells (MDSCs); and inhibiting CD8⁺ T cell anti-tumour functions by impairing the ability of tumour cells to directly present tumour antigen, inhibiting dendritic cell differentiation and switching the function of dendritic cells from induction of immunity to T cell tolerance. The yellow CD8⁺ T cells have anti-tumour activity and the purple CD8⁺ T cell does not have anti-tumour activity. The purple dendritic cells have the ability to present tumour antigens from tumour cells with major histocompatibility complex (MHC) class I molecules to activate naive CD8⁺ T cells. The orange dendritic cell does not have the ability to activate CD8⁺ T cells (T cell tolerance). IFNγ, interferon-γ; IL, interleukin; TNFα, tumour necrosis factor-α.




Figure 6. A model of PGE₂ and LTB₄ coordinately regulating angiogenesis in the tumour microenvironment

Pro-inflammatory prostaglandin E₂ (PGE₂) and/or B₄ LTB₄ promote angiogenesis on at least two levels. First, PGE₂ and/or LTB₄ can directly act on epithelial, endothelial and/or immune cells to induce angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2) and the chemokines CXCL1 and CCL2. In transformed epithelial cells, PGE₂ induces VEGF and CXCL1 secretion through an EP2 or EP4–epidermal growth factor (EGFR)–Erk cascade. In endothelial cells, PGE₂ induces VEGF and FGF2 secretion through a MAPK pathway and LTB₄ also stimulates VEGF expression. Moreover, PGE₂ not only binds to endothelial cells to stimulate cell migration through an αVβ3 integrin–CDC42 and Rac pathway, but also mediates VEGF- and FGF2-induced CXCR4-dependent neovessel assembly *in vivo*. In immune cells, PGE₂ promotes mast cells to release VEGF and CCL2, and LTB₄ stimulates VEGF expression. Secretion of VEGF and FGF2 from tumour epithelial, endothelial and immune cells promotes endothelial cell proliferation and survival, and the chemokine CXCL1 released from tumour epithelial cells stimulates endothelial cell migration and tube formation *in vitro* and angiogenesis *in vivo*. CCL2 can attract endothelial cells to the tumour microenvironment. Interestingly, VEGF and FGF2 induce COX2 and subsequently PGE₂ in endothelial cells, and CCL2 also induces COX2 and PGE₂ in macrophages. Therefore, the effects of PGE₂ on the regulation of VEGF, FGF2 and CCL2 are probably amplified through this positive feedback loop.

Table 1
Signals that mediate the effects of eicosanoids on carcinoma cell proliferation, survival, and migration and invasion

Lipids	Receptors	Pathways	Functions	Tumour type	In vitro	In vivo*	refs
PGE ₂	EP1-4 [‡]	Ras-Erk	Proliferation	Colorectal	+	+	46
	EP1-4 [‡]	Ras-Erk	Proliferation	Non-small-cell lung	+		48
	EP2	GSK3β-β-catenin	Proliferation	Colorectal	+		47
	EP1-4 [‡]	PI3K-Akt-PPARδ	Survival	Colorectal	+	+	10
	EP1-4 [‡]	BCL-2	Survival	Colorectal	+		50
	EP1-4 [‡]	NF-κB	Survival	Colorectal	+		51
	EP4	SRC-EGFR-PI3K-Akt	Migration and invasion	Colorectal	+	+	61,62
	EPI	SRC-EGFR	Migration and invasion	Hepatocellular	+		63
	EP1-4 [‡]	Erk-ETS1	Migration and invasion	Pancreatic	+		65
	EP2 and EP4	CCR7	Migration and invasion	Breast	+		66
	EP4	PI3K-Akt	Migration and invasion	Lung and colorectal	+	+	67
PGF _{2α}	FP	Erk-FGF2-FGFR1-Erk	Proliferation	Endometrial	+		52
	FP	?	Migration and invasion	Colorectal and endometrial	+		68, 69
PGD ₂	PPARδ	?	Proliferation inhibition	Prostate	+		53
TXA ₂	TP	RHOA	Migration	Prostate	+		70
LTB ₄	BLT1	Mek-Erk and PI3K-Akt	Proliferation	Pancreatic	+		56
	BLT1	Erk	Survival	Colorectal	+		55
	?	?	Migration and invasion	Pancreatic		+	71
LTD ₄	CysLTI-2 [‡]	GSK3β-β-catenin	Survival	Intestinal	+		57
	CysLTI	PKC-Raf-Erk	Proliferation and survival	Intestinal	+		58
	CysLTI-2 [‡]	COX2 and BCL-2	Survival	Intestinal	+		59
	CysLTI	?	Proliferation	Colorectal	+		60

Lipids	Receptors	Pathways	Functions	Tumour type	In vitro	In vivo*	refs
	CysLTI	?	Survival	Prostate	+		44
	CysLTI-2 [‡]	PI3K-Akt-Rac	Migration	Intestinal	+		72

BLT1, leukotriene B4 receptor (also known as LTB4R); CCR7, C-C chemokine receptor 7; COX2, cyclooxygenase 2; CysLTI, cysteinyl leukotriene receptor 1; EGFR, epidermal growth factor receptor; EPI, prostaglandin E receptor 1; FGF2, fibroblast growth factor 2; FGFR1, FGF receptor 1; FP, prostaglandin F receptor; GSK3 β , glycogen synthase kinase 3 β ; LTB4, leukotriene B4; NF- κ B, nuclear factor- κ B; PGE2, prostaglandin E2; PKC, protein kinase C; PPAR δ , peroxisome proliferator-activated receptor- δ ; TXA2, thromboxane A2; TP, TXA2 receptor.

* *In vivo* indicates animal studies.

[‡]No data available on which receptor mediates the effects of the lipid.